Helsinn buys glob­al rights for skin can­cer drug from Acte­lion; Ake­bia reels in more cash for vadadu­s­tat; EMA slams Bevyxxa

→ Swiss phar­ma group Helsinn is ac­quir­ing rights to skin can­cer drug Valchlor (mar­ket­ed as Leda­ga in Eu­rope) from Acte­lion Phar­ma­ceu­ti­cals. The deal gets Helsinn …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER